The FDA meeting outcome is a positive catalyst for CGTX, reducing regulatory risk for the DLB psychosis program. Traders should watch for formal FDA minutes in June and any subsequent trial design details. The stock may see upward momentum on this news, but given the early stage and historical volatility, position sizing should account for binary risk.
Price Chart
Executive Summary
Cognition Therapeutics held a productive FDA meeting on May 20, 2026, to discuss Phase 2 SHIMMER study results for zervimesine (CT1812) in dementia with Lewy bodies (DLB) with psychosis. The company believes it has a path forward for a registrational program, with formal FDA minutes expected in June. This is a positive regulatory milestone for a clinical-stage biotech with a $115M market cap, but no definitive approval or data readout was announced.
Key Facts
- Productive FDA meeting on May 20, 2026, to discuss Phase 2 SHIMMER study results for zervimesine (CT1812) in DLB with psychosis.
- Company believes it has a path forward for a registrational program; formal FDA minutes expected in June.
- Zervimesine is an oral therapy targeting toxic oligomers; Phase 2 studies completed in DLB, mild-to-moderate Alzheimer's, and geographic atrophy.
- Backed by nearly $200 million in NIH and foundation grants.
- Market cap ~$115M; 90% analyst consensus bullish (2 Strong Buy, 7 Buy, 1 Hold).
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue.
Risk Factors
- Formal FDA minutes may include conditions or requirements that alter the registrational path.
- Clinical-stage biotech with no approved products; high execution risk and capital needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299218 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.7010 $0.7188 | ▲ +2.54% | ▲ +3.06% | $0.7196 (+2.65%) |
Jun 4, 2026 20w ago | 8-K | $1.36 $1.29 | ▼ −5.15% | ▼ −2.55% | $0.7196 (−47.09%) |
Jun 1, 2026 21w ago | Press Release | $1.25 $1.35 | ▲ +8.00% | ▲ +7.86% | $0.7196 (−42.43%) |
May 21, 2026 22w ago | Press Release | $1.25 $1.26 | ▲ +0.80% | ▲ +0.35% | $0.7196 (−42.43%) |
May 14, 2026 23w ago | Press Release | $1.20 $1.14 | ▼ −5.00% | ▼ −3.77% | $0.7196 (−40.03%) |
May 7, 2026 24w ago | 8-K | $1.21 $1.18 | ▼ −2.48% | ▼ −2.71% | $0.7196 (−40.53%) |
Apr 16, 2026 27w ago | Insider Cluster | $1.11 $1.19 | ▲ +7.21% | ▲ +5.99% | $0.7196 (−35.17%) |
Mar 26, 2026 30w ago | Press Release | $1.08 $0.7300 | ▼ −32.41% | ▼ −30.73% | $0.7196 (−33.37%) |
Mar 23, 2026 31w ago | Press Release | $1.13 $1.10 | ▼ −2.65% | ▼ −2.30% | $0.7196 (−36.32%) |
Mar 17, 2026 31w ago | Press Release | $1.15 $1.10 | ▼ −4.35% | ▼ −2.95% | $0.7196 (−37.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers